复方异丙托溴铵联合孟鲁司特钠治疗AECOPD患者的疗效及对MCP-1、RDW、NLR的影响

Efficacy of Compound Ipratropium Bromide Combined with Montelukast Sodium in the Treatment of Patients with AECOPD and Its Influence on MCP-1,RDW and NLR

目的:观察复方异丙托溴铵联合孟鲁司特钠治疗慢性阻塞性肺疾病急性加重(AECOPD)患者的疗效,及对血清单核细胞趋化蛋白-1(MCP-1)、红细胞分布宽度(RDW)及中性粒细胞淋巴细胞比值(NLR)的影响。方法:94例AECOPD患者随机分为两组各47例,对照组雾化吸入复方异丙托溴铵,研究组在对照组基础上联合孟鲁司特钠,均连续治疗14 d。观察两组临床疗效、临床症状消失时间和药品不良反应,比较两组治疗前后肺功能、外周血嗜酸性粒细胞(EOS)百分比、MCP-1、RDW、NLR水平变化。结果:治疗后研究组总有效率明显高于对照组(P<0.05),临床症状消失时间短于对照组(P<0.05),但两组药品不良反应发生率差异无统计学意义(P>0.05)。治疗后,两组患者各项肺功能指标均较前提高,外周血EOS百分比、血清MCP-1水平及RDW、NLR则较前降低(P<0.05);且研究组上述指标均优于对照组(P<0.05)。结论:复方异丙托溴铵联合孟鲁司特钠治疗AECOPD可更有效减轻气道炎症反应,缓解临床症状,改善肺功能,且安全性高。

Objective:To observe the efficacy of compound ipratropium bromide combined with montelukast sodium in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD),and the influence of serum monocyte chemoattractant protein-1(MCP-1),red blood cell distribution width(RDW)and neutrophil lymphocyte ratio(NLR).Methods:A total of 94 cases of AECOPD patients were divided into two groups,47 cases in each group,the control group was nebulized inhaled compound ipratropium bromide,the research group added montelukast sodium on the basis of the control group,the both groups were treated continuously for 14 days.The clinical efficacy,pulmonary function,percentage of eosinophils(EOS)in peripheral blood,MCP-1,RDW and NLR before and after treatment,clinical symptoms disappeared and adverse reactions were compared between the two groups.Results:The total effective rate after treatment of the research group was significantly higher than that of the control group(P<0.05).The clinical symptoms disappeared of the research group were significantly earlier(P<0.05),but there was no statistically significant difference in the incidence of total adverse reactions(P>0.05).The percentage of EOS in peripheral blood,serum MCP-1 level and NLR,RDW after treatment of the two groups decreased,the research group were lower than the control group(P<0.05).Conclusion:Compound ipratropium bromide combined with montelukast sodium in the treatment of AECOPD can more effectively reduce airway inflammation,alleviate clinical symptoms,improve lung function,have high safety.